About this Journal Submit a Manuscript Table of Contents

Novel Therapeutic Strategies for Glomerulonephritis

Call for Papers

Current immunotherapy for glomerulonephritis (GN) consists of corticosteroids and cytotoxic drugs are nonspecific blockade of the immune system and so their use is associated with variety of side effects. Over the last decade, the advance in understanding of the complex pathogenesis underlying GN has paved the way for development of molecular targeted therapy for GN, including rituximab for refractory nephritic syndrome in children, antineutrophil-cytoplasmic-antibody- (ANCA-) associated GN and membranous nephropathy, eculizumab for atypical hemolytic uremic syndrome, and belimumab for lupus nephritis (LN). Recently, experimental studies have identified a number of molecular therapeutic targets and new therapeutic options in GN.

We invite investigators to contribute original research articles as well as review articles, on new molecular targets or novel strategies for the treatment of GN. Potential topics include, but are not limited to:

  • New molecular pathways involved in GN that are potential therapeutic targets
  • Recent advances in clinically relevant therapeutic strategies using animal models
  • Innovative concepts in the treatment of GN (small molecules, stem cells, gene therapy, etc.)
  • Novel therapeutic targets in podocytes

Before submission, authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/nephrology/glomer/ according to the following timetable:

Manuscript DueFriday, 25 April 2014
First Round of ReviewsFriday, 18 July 2014
Publication DateFriday, 12 September 2014

Lead Guest Editor

  • Masayuki Iyoda, Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

Guest Editors

  • Takashi Yokoo, Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
  • Takashi Wada, Division of Nephrology, Department of Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
  • Michael S. Goligorsky, New York Medical College, Valhalla, NY, USA